CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 822 enrolled
Drug / intervention
Combination NRT (Nicotine patch, Nicotine lozenge) +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02351167
NCT02351167Phase 4Completed
CompareCT.gov

Genetically Informed Smoking Cessation Trial

Washington University School of Medicine·interventional·Posted Jan 30, 2015·Updated Sep 22, 2020

In Brief

A Phase 4 clinical trial evaluating Combination NRT (Nicotine patch, Nicotine lozenge), Varenicline, and 2 other interventions for Smoking Cessation. Completed, enrolled 822 participants across 1 site.

Detailed Summary

The investigators' goal is to identify the most appropriate smoking cessation treatments for smokers based on genetic information. Smokers try to quit smoking but relapses are common.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmoking Cessation
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 30, 2015
Enrollment StartMay 20, 2015
Primary CompletionDec 26, 2018
Study CompletionAug 31, 2019
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 11.4 years ago

Interventions

Combination NRT (Nicotine patch, Nicotine lozenge)drug

Vareniclinedrug

Placebodrug

Intensive smoking counselingbehavioral